Using artificial intelligence to help diagnose prostate cancer
Safety and Accuracy of Artificial Intelligence-aided Precision MRI Assessment for the Optimization of Prostate Biopsy in Men With Suspicion of Prostate Cancer: a Multicenter Randomized Controlled Trial.
This study is testing whether using artificial intelligence can help doctors better diagnose prostate cancer through MRI scans for men who might have the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 60 Years to 90 Years |
| Sex | Male |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing) |
| Trial ID | NCT05513638 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the application of artificial intelligence (AI) to improve the diagnosis of prostate cancer through magnetic resonance imaging (MRI). It aims to address the challenges of inter-reader variability and the high level of expertise required for accurate interpretation of MRI results. By leveraging AI, the study seeks to enhance the consistency and reliability of prostate cancer detection and staging, potentially leading to better patient outcomes. Participants will be evaluated based on their clinical suspicion of prostate cancer, indicated by elevated prostate-specific antigen levels or abnormal digital rectal examinations.
Who should consider this trial
Good fit: Ideal candidates for this study are men who are clinically suspected of having prostate cancer, particularly those with elevated prostate-specific antigen levels or abnormal digital rectal examinations.
Not a fit: Patients under 60 years of age or those who have previously undergone surgery, radiotherapy, or drug therapy for prostate cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and consistent diagnoses of prostate cancer, improving treatment outcomes for patients.
How similar studies have performed: Other studies have shown promise in using AI for medical imaging, indicating that this approach could be a meaningful advancement in prostate cancer diagnosis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical suspicious of prostate cancer, presenting with an elevated prostatic specific antigen and/or abnormal digital rectal examination Exclusion Criteria: * (1) \<60 years of age; (2) a previous surgery, radiotherapy or drug therapy for prostate cancer (interventions for benign prostatic hyperplasia or bladder outflow obstruction were deemed acceptable); (3) incomplete mp-MRI examination or artifacts of the images.
Where this trial is running
Nanjing
- Yu-Dong Zhang — Nanjing, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.